Allogene Therapeutics (ALLO) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 18, 2026, and will be held virtually, allowing shareholders to vote and ask questions online.

• Key proposals include electing three directors, advisory votes on executive compensation and its frequency, amending the certificate to increase authorized shares, and ratifying the external auditor.

• 2025 highlights include clinical progress in oncology and autoimmune programs, operational realignment, and maintaining sufficient inventory for trials.

Voting matters and shareholder proposals

• Election of three directors for terms expiring in 2029.

• Advisory approval of executive compensation and preferred frequency of say-on-pay votes (Board recommends annual votes).

• Amendment to increase authorized common stock from 400M to 800M shares.

• Ratification of Ernst & Young LLP as independent auditor for 2026.

Board of directors and corporate governance

• Board will reduce from eleven to ten members after the meeting, with a focus on strategic skills for commercialization.

• Board is classified into three classes with staggered three-year terms.

• Majority of directors are independent; leadership structure includes an Executive Chair and Lead Independent Director.

• Annual board self-evaluation and use of an independent advisor for assessment.

• Committees include Audit, Compensation, Nominating and Corporate Governance, International and Business Development Oversight, and Research and Development.